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JmjC domain-containing protein 6 (JMJD6) is a 2-oxo-
glutarate (2OG)-dependent oxygenase linked to various cellular
processes, including splicing regulation, histone modification,
transcriptional pause release, hypoxia sensing, and cancer.
JMJD6 is reported to catalyze hydroxylation of lysine residue(s)
of histones, the tumor-suppressor protein p53, and splicing reg-
ulatory proteins, including u2 small nuclear ribonucleoprotein
auxiliary factor 65-kDa subunit (U2AF65). JMJD6 is also
reported to catalyze N-demethylation of N-methylated (both
mono- and di-methylated) arginine residues of histones and
other proteins, including HSP70 (heat-shock protein 70), estro-
gen receptor , and RNA helicase A. Here, we report MS- and
NMR-based kinetic assays employing purified JMJD6 and mul-
tiple substrate fragment sequences, the results of which support
the assignment of purified JMJD6 as a lysyl hydroxylase. By con-
trast, we did not observe N-methyl arginyl N-demethylation
with purified JMJD6. Biophysical analyses, including crystallo-
graphic analyses of JMJD6344 – 403 in complex with iron and
2OG, supported its assignment as a lysyl hydroxylase rather
than an N-methyl arginyl-demethylase. The screening results
supported some, but not all, of the assigned JMJD6 substrates
and identified other potential JMJD6 substrates. We envision
these results will be useful in cellular and biological work on the
substrates and functions of JMJD6 and in the development of
selective inhibitors of human 2OG oxygenases.
There are 60 –70 human 2-oxoglutarate (2OG,3 -ketogl-
utarate) and ferrous iron-dependent oxygenases with diverse
biological roles, including in collagen biosynthesis, lipid metab-
olism, hypoxia sensing, DNA damage repair, and epigenetic
regulation (1). Most 2OG oxygenases catalyze two-electron
oxidations that are coupled to the conversion of 2OG to succi-
nate and carbon dioxide (Fig. 1A) (1, 2). Several human 2OG
oxygenases are current clinical drug targets, including the
hypoxia-inducible factor prolyl hydroxylases (PHDs) and -bu-
tyrobetaine hydroxylase (BBOX1) (2, 3).
The JmjC subfamily of 2OG oxygenases is relevant to cancer
and other diseases, with functional roles as histone N-methyl
lysyl and N-methyl arginyl demethylases (KDMs and RDMs,
respectively) (Fig. 1B) (4). JmjC 2OG oxygenase catalyzed
N-methyl lysyl demethylation proceeds via initial hydroxyl-
ation to give a hemiaminal nascent product that normally frag-
ments to give the demethylated product and formaldehyde (Fig.
1B) (5). In isolated form, some human JmjC KDMs reportedly
manifest a low level of RDM activity (Fig. 1B), but the cellular
relevance of this remains unclear (4).
A subset of JmjC 2OG oxygenases catalyze the formation of
stable alcohol products via the hydroxylation of protein residue
side chains (Fig. 1C) (1, 6, 7). A prototypical JmjC “hydroxylase”
is factor-inhibiting hypoxia-inducible factor (FIH). FIH cata-
lyzes the C-3 hydroxylation of an asparagine residue in the
hypoxia-inducible transcription factor (HIF), a modification
that serves to regulate the transcriptional activity of HIF, as well
as various residues in ankyrin repeat domain proteins (8, 9).
Other human 2OG-dependent JmjC “hydroxylases” have been
characterized including JMJD5 (an arginyl C-3R hydroxylase),
JMJD7 (a lysyl C-3S hydroxylase), and the ribosomal oxyge-
nases MINA53 and NO66 (both histidine-residue C-3S
hydroxylases) (1, 6, 10 –12). Many of the reactions catalyzed by
these JmjC hydroxylases appear to be involved in the regulation
of the translation machinery, including via modifications to
ribosomally-associated proteins (1, 6, 10 –12). Structural differ-
ences at the active sites and surrounding regions are proposed
to distinguish typical JmjC KDMs and JmjC hydroxylases (7, 10,
13), although given the promiscuity of 2OG oxygenase catalysis,
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care should be taken in assigning biochemical functions from
sequences/structures (1, 2).
JMJD6 is a particularly interesting JmjC family member (14),
including from the perspective of its reported enzymatic activ-
ities. JMJD6 has been assigned both N-methyl arginyl demeth-
ylase and lysyl C-5 hydroxylase activities (Fig. 1C) (15–17). The
protein corresponding to JMJD6 was initially characterized as
the phosphatidylserine receptor (PTDSR) with a consequently
associated role in apoptosis (18). Subsequent work, however,
established that PTDSR is unlikely to be a membrane protein,
instead localizing to the nucleus (19, 20), although it is present
elsewhere in the cell (20, 21). Structurally informed bioinfor-
matics led to the prediction that JMJD6 has a JmjC domain
containing the modified double-stranded -helix (DSBH) fold
(Fig. S1) that is characteristic of the Fe(II) and 2OG-dependent
oxygenases (19, 20, 22). PTDSR was thereafter renamed JMJD6
(19, 23). JMJD6, like FIH (24, 25), contains one domain and
forms a homodimer both in solution and in crystals (Fig. S1)
(23, 26). Human JMJD6 also has five predicted nuclear localiza-
tion sequences (Lys6–Arg10, Lys91–Arg95, Pro141–Lys145,
Lys167–Pro171, and Arg373–Arg378), a predicted AT-hook motif
(Lys283–Ser326), a potential SUMOylation site (Leu316–Asp319),
and a C-terminal polyserine (poly-Ser) region (Ser340–Ser359,
with four interspersed aspartate residues) (19, 20); the JMJD6
poly-Ser region is involved in regulating its oligomerization and
cellular localization (Fig. S1) (20, 21).
Figure 1. Schematic of 2OG-catalyzed hydroxylation and demethylation oxidation reactions. A, outline mechanism of a 2OG-dependent oxygenase
catalytic cycle; one atom of O2 is incorporated into the substrate (R–H), a process coupled to the oxidative decarboxylation of 2OG to give succinate and CO2.
B, reactions catalyzed by JmjC KDMs and JmjC RDMs, C, JMJD6-catalyzed lysyl C-5 hydroxylation.
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Chang et al. (15) assigned JMJD6 as an histone N-methyl
arginyl demethylase (RDM) acting on mono- and symmetric/
asymmetric di-methyl forms of arginine residues as observed in
studies with isolated enzyme (Fig. 1B). JMJD6 is also reported to
catalyze RDM reactions on N-methylated forms of heat-shock
protein 70-kDa (HSP70) (27), estrogen receptor  (ER) (28),
RNA helicase A (29), and the stress granule-nucleating protein
G3BP1 (GTPase-activating protein SH3-domain– binding pro-
tein stress granule assembly factor 1) (30). Although evidence
for the interaction of JMJD6 with histones has been observed by
several groups, its reported RDM activity is less clear (17, 31,
32).
Subsequent to its assignment as an RDM, JMJD6 was
reported to catalyze lysine C-5 hydroxylation (Fig. 1C) of the
splicing regulatory (SR) proteins luc-7–like 2 (LUC7L2), cispla-
tin resistance-associated overexpressed protein (CROP), and
u2 small nuclear ribonucleoprotein auxiliary factor 65-kDa
subunit (U2AF65) (17). JMJD6-catalyzed hydroxylation has
been reported to give the lysine C-5– hydroxylated product
with the (5S)-stereochemistry (Fig. 1C) (16), contrasting with
lysine residue hydroxylation by the procollagen lysine-hy-
droxylases which proceeds to give the (5R)-product (33).
JMJD6 is also reported to undergo self-hydroxylation of
lysine residues (34). More recently, the tumor-suppressor
protein p53 has been reported to be a JMJD6 hydroxylation
substrate (35).
JMJD6 has an apparent role in growth development, with
JMJD6-knockout mice dying near birth due to growth impair-
ment of multiple organs, including heart, brain, lung, kidney,
and eye (36). JMJD6 has been linked to cancer (28, 35), and its
hydroxylase activity is linked to preeclampsia via regulation of
the HIF system in the placenta (37, 38). However, the details of
how these pathophysiological observations are linked to JMJD6
catalytic activity are unclear.
Here, we describe biochemical and biophysical studies on
isolated JMJD6 using multiple substrates reported as targets for
JMJD6-catalyzed lysine-residue hydroxylation and N-methyl
arginyl demethylation. The combined results support the
assignment of purified JMJD6 as a lysyl C-5 hydroxylase rather
than an N-methyl arginyl demethylase. This assignment is con-
sistent with crystallographic studies of JMJD6 with its natural
ferrous iron cofactor and 2OG cosubstrate; these results imply
that the JMJD6 active site is more similar to the JmjC hydroxy-
lases, such as FIH, rather than the JmjC demethylases. We
intend that the results will aid in the accurate assignment of
JMJD6 substrates in the cellular context and hence help to
define its physiological roles.
Results
Because our objective was to investigate the catalytic reac-
tions catalyzed by isolated JMJD6, the activity of which can
be compromised due to oligomerization (14, 31), we initially
investigated the catalytic activity of JMJD6 variants: full-length
JMJD6 (residues 1– 403, JMJD6FL), and two C-terminally
truncated variants, i.e. JMJD6 comprising residues 1–362
(JMJD6363– 403) and residues 1–343 (JMJD6344 – 403) (Fig.
S1A). Circular dichroism (CD) spectroscopic analyses imply
similar secondary structure content for each of the three JMJD6
variants (Fig. S1B).
Hydroxylation assays using the reported LUC7L2267–278 sub-
strate (17) revealed moderately increased hydroxylation activ-
ity for JMJD6363– 403 and JMJD6FL, both having the poly-Ser
region, when compared with JMJD6344 – 403 lacking the poly-
Ser region (Fig. S1C). The apparent binding constant (KDapp) of
2OG was determined using CPMG-edited NMR (39); the
KDapp values were 3.5, 3.0, and 2.5 M for JMJD6344 – 403,
JMJD6363– 403, and JMJD6FL, respectively, i.e. essentially the
same within experimental error (Table 1 and Fig. S2A). Kmapp
values for 2OG were determined using the standard hydroxyl-
ation assay procedure and were 31, 24, and 45 M for JMJD6FL,
JMJD6363– 403,andJMJD6344 – 403,respectively(Fig.S2B),con-
sistent with Mantri et al. (23) who reported a Kmapp for 2OG as
39 M for JMJD6FL. NMR monitoring of 2OG turnover in the
absence of substrate revealed JMJD6344–403, JMJD6363–403, and
JMJD6FL produce 0.50, 6.4, and 0.90 M of succinate, respectively,
after 1.5 h (Table 1 and Fig. S3). In the presence of the LUC7L2267–278
substrate with JMJD6344–403, JMJD6363– 403, and JMJD6FL,
these values increased to 1.8, 8.4, and 3.6 M succinate,
respectively (Table 1 and Fig. S3). Thus, under both assay
conditions, succinate formation for JMJD6363– 403 and
JMJD6FL was higher than JMJD6344 – 403, indicating a possi-
ble role of the C-terminal poly-Ser region in enhancing catal-
ysis and/or of active protein stability. However, given the
role of the poly-Ser region in oligomerization (21) and the
potential for JMJD6 to catalyze hydroxylation of itself (34),
the mechanistic interpretation of these results is uncertain.
The 2OG turnover assay was also carried out using EDTA-
treated JMJD6363– 403, with freshly prepared Fe(II) solution
being added prior to reaction, with the same outcome, i.e.
with the poly-Ser region containing proteins being more
active (Table 1 and Fig. S4). Given that JMJD6363– 403 was
the most active and stable variant tested, further assays were
conducted with it.
Table 1
Summary of binding parameters for the cosubstrate 2OG with JMJD6 variants
Succinate formation was monitored in reactions carried out under standard 2OG turnover assay conditions. Values in parentheses are total M of succinate formed in the
2OG turnover assay using EDTA-treated JMJD6 (with Fe(II) added prior to reaction). KDapp values were determined by following CPMG-edited signals of 2OG titrated
against JMJD6. To determine the apparent kinetic parameter (Kmapp), standard hydroxylation assay conditions were followed with varied concentrations of 2OG (0 –150
M). Values represent mean  S.D. (n  3).
Variant
Succinate production 2OG
Without substrate With substrate KDapp Kmapp
M M
JMJD6FL 0.90  0.030 (8.0  0.030) 3.6  0.030 (39  0.020) 2.3  1.6 31  5.3
JMJD6363–403 6.4  0.020 (12  0.040) 8.4  0.020 (44  0.060) 3.0  4.8 24  5.4
JMJD6344–403 0.50  0.020 (1.6  0.050) 1.8  0.030 (5.8  0.030) 3.5  2.1 45  10
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Isolated JMJD6 does not show RDM activity under our assay
conditions
Three histone peptides with symmetrically di-methylated
arginine residues, all of which have been reported as JMJD6
RDM substrates (15, 40), were tested using JMJD6363– 403




biotin (40). JMJD2E (KDM4E) was used as a positive control for
RDM activity (4). Matrix-assisted laser desorption ionization-
TOF (MALDI-TOF) mass spectrometry (MS)-based assays
revealed no shift in the masses for peptides in the no-enzyme
controls(Fig.2).PeptidestreatedbyJMJD2Emanifesteddemeth-
ylation (peaks with 14 and 28 Da mass shifts) (Fig. 2). By
contrast, JMJD6363– 403 incubations under the same condi-
tions manifested mass shifts of 16, 32, and 48 Da but not
of 14 or 28 Da, suggesting JMJD6363– 403 catalyzes hydrox-
ylation but does not have RDM activity under our assay condi-
tions (Fig. 2). The samples were then analyzed by LC-coupled
MS (LC-MS/MS), which showed evidence for demethylation of
residues R2histone3 and R3histone4 in the presence of JMJD2E
(Figs. S5–S13). When treated with JMJD6, hydroxylation of
K4histone3, K9histone3, K14histone3, K5histone4, and K8histone4 was
observed (Figs. S5–S13), consistent with the MALDI results.
Note, we did not accrue any evidence for JMJD6 catalyzed hy-
droxylation of arginine residues as reported for JMJD5 (12).
These results contrast with those of Chang et al. (15), who
reported JMJD6 RDM activity on H3R2(me2s)1–25 and
H4R3(me2s)1–30 (although their MS results also support
hydroxylation).
Evidence for JMJD6363– 403-catalyzed hydroxylation of
lysine residues was also observed with analogous histone pep-
tides H31–25 and H41–30 with unmodified arginine residues
(Fig. S14). Furthermore, when a histone peptide monomethy-
lated at Lys9 (H3K9me11–17) was tested with JMJD6363– 403, a
16-Da mass shift was observed, implying hydroxylation and
not demethylation (Fig. S15). This observation also suggests
JMJD6 does not catalyze histone lysyl demethylation, consis-
tent with an earlier report (17). The level of hydroxylation of
Figure 2. Evidence that isolated JMJD6 is not a histone N-methyl arginyl demethylase. LC-MS spectra of H4R3(me2s)1–30 (A), H3R2(me2s)1–25 (B), and
H4R3(me2s)1–18-K-biotin (C) show the unmodified peptides in the presence of all reaction components except enzyme (black spectra). Red spectra show peaks
with 16-Da mass shifts observed in the presence of JMJD6363– 403. By contrast, blue spectra show peaks with 14- and 28-Da mass shifts for the JmjC KDM
JMJD2E/KDM4E-treated peptides suggesting demethylation. Note the lack of evidence for demethylation in the JMJD6-treated substrates. Adduct, apparent
non-enzymatic peptide modification.
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Lys9(me1) compared with Lys9 was relatively low (Fig. 2 and
Figs. S14 and S15), which suggests that under our assay condi-
tions JMJD6 prefers to hydroxylate unmodified lysine residues
and provides evidence that JMJD6-catalyzed lysyl hydroxyl-
ation has the potential to be affected by N lysine modifications.
HSP70 has been reported as a JMJD6 substrate wherein the
mono-methylated arginine residue (Arg469) is demethylated by
JMJD6 as observed by MS (27). However, with JMJD6363–403 and
a similar peptide to that reported, but without an N-terminal bio-
tin, once again we did not observe demethylation (Fig. S16).
Steady-state kinetics of JMJD6 catalysis
Heim et al. (41) have reported JMJD6 interacts with arginine-
serine (RS)-rich regions of U2AF65, LUC7L2, SRSF11 (serine/
arginine-rich splicing factor 11), and Acinus S (apoptotic
chromatin condensation inducer in the nucleus), but not with
the RS region of SRSF1 (serine/arginine-rich splicing factor 1).
Peptides spanning the RS regions of these SR proteins were
made and tested as JMJD6363– 403 substrates, initially screen-
ing with fixed time assays and MALDI-TOF MS. The results
revealed JMJD6363– 403-dependent hydroxylation (16-Da
mass shift) (Fig. 3 and Table 2). To investigate whether the
observed 16 Da shifts are due to lysyl hydroxylation and the
sites of hydroxylation, the lysine residues were systematically
replaced by alanine residues. The results enabled assignment of
the hydroxylated lysine residues (Figs. S17–S21). Time-course
assays were then performed (Fig. S22), with peptides displaying
25% hydroxylation after 6 min in kinetic studies (Table 2).
The kinetic parameters obtained for LUC7L2267–278 were as
follows: Kmapp, 51.0 M; kcat, 106 	 104 s1; and kcat/Kmapp,
208 	 106 M1s1. Of the tested U2AF65 peptide frag-
ments, U2AF6521–35 (Kmapp, 59.0 M; kcat/Kmapp, 68.0 	 106
M1s1) was found to be a better substrate than
U2AF6530 – 46 (Kmapp, 78.0 M; kcat/Kmapp, 118 	 106
M1s1) and U2AF6555–70 (Kmapp, 124 M; kcat/Kmapp, 34.0 	
106 M1s1) (Table 2 and Fig. S23). Other peptides tested,
e.g. from the SR protein CROP, gave similar kinetic parameters
(CROP Kmapp value 90.0 M). Of the SRSF11 fragments
tested, JMJD6363– 403 hydroxylated SRSF11358 –372 with a rela-
tively high efficiency (Kmapp, 41.0 M; kcat/Kmapp, 195 	 106
M1s1). With RBM39 (RNA-binding protein 39), hydroxyl-
ation levels were found to vary with measured Kmapp values
ranging within 56.0 –99.0 M (Table 2 and Fig. S23). Of the
tested RBM39 fragments, RBM3931– 42 was substantially more
efficiently hydroxylated than the others tested, with Kmapp 56.0
M and kcat/Kmapp 455 	 106 M1s1. These results are
consistent with the proposal that JMJD6 is promiscuous with
respect to its lysyl hydroxylase activity in cells (17, 41); the vari-
ations in activities observed imply that more efficient substrates
than those studied here are likely to exist within cells.
JMJD6 hydroxylates lysine residues in pVHL and ER
fragments
The apparent promiscuity of isolated JMJD6 with RS
domains of SR proteins prompted us to test the potential of
other reported JMJD6 substrates. The von Hippel-Lindau pro-
tein (pVHL) has been reported as a potential JMJD6 substrate
(37) and was of special interest because of its pivotal role in the
hypoxic response via binding hydroxyproline residues in the
hypoxia-inducible transcription factors that are produced by
2OG oxygenase catalysis (1, 42). We selected three lysine-con-
taining pVHL sequences for testing with JMJD6363– 403;
MALDI-TOF analysis revealed the presence of a 16-Da mass
shift for pVHL166 –177, but not for pVHL154 –165 or pVHL189 –200
(Fig. S24A), suggesting possible hydroxylation of Lys171. Assays
with the alanine variant pVHL166 –177K171A and with WT
pVHL166 –177 in the presence of a JMJD6 inhibitor, 2,4-pyridine
dicarboxylic acid (2,4-PDCA),4 did not manifest hydroxylation
(Fig. S24B). LC-MS/MS analysis of JMJD6363– 403-treated
pVHL166 –177 provided further evidence for pVHL Lys171 hy-
droxylation (Fig. S24, C–E).
Based on Western blot analysis, it has been reported that
JMJD6 catalyzes N-demethylation of methylated (asymmetrically
di-methylated) Arg260 of ER and thereby regulates methylated
ER function in response to estrogen (28). Peptides encompassing
residues 251–262 of ER with symmetrically as well as asymmet-
rically di-methylated Arg260 (MKGGIRKDRR(me2s/a)GG) were
tested with JMJD6363–403, and ER demethylation was not
observed (Fig. S25A). Interestingly, a 16-Da mass shift, corre-
sponding to hydroxylation, was observed for both peptides (Fig.
S25A). In light of the results with histone peptides, we considered
it possible that JMJD6 catalyzes hydroxylation of either or both of
the lysine residues (Lys252 and Lys257) in the ER sequence. Assays
using ER peptides with unmodified Arg260 also revealed
JMJD6363–403-dependent hydroxylation (Fig. S25B). Hydroxyla-
tion was ablated by alanine substitution ER251–262K252A,
ER251–262K257A, or by addition of the JMJD6 inhibitor 2,4-
PDCA4 (Fig. S25, C and D). These results suggest Lys252 and Lys257
of ER are possible targets for JMJD6 hydroxylation and are fur-
ther evidence that JMJD6-catalyzed hydroxylation is possibly reg-
ulated by other post-translational modifications.
JMJD6 lysyl hydroxylase activity has also been associated
with post-translational modification of the tumor-suppressor
protein p53, wherein the target residue is Lys382 (35). Assays
with JMJD6363– 403 validated this observation, i.e. a 16-Da
mass shift of p53 was observed under standard assay conditions
implying hydroxylation (Fig. S26).
Crystallographic studies on JMJD6
Crystallization trials were carried out using the three JMJD6
variants. Crystallization of JMJD6344 – 403 in the presence of
Fe(II) and 2OG was performed in an anaerobic glove box as
reported for FIH (Table 3 and Fig. 4) (24).
The JMJD6344 – 403Fe2OG crystals belong to the same
space group (P21) with similar unit cell dimensions to that
reported by Mantri et al. (23) (Table S1). The structure was
solved by molecular replacement using PDB code 3K2O as a
search model (23). JMJD6344 – 403 crystallizes as a homodimer
with two molecules in the asymmetric unit (Fig. 4) having a total
buried surface area of 2086 Å2 (calculated iG 16.8
kcalmol1) with no Ramachandran or side-chain conforma-
tional isomer outliers (Table 3), consistent with the previously
reported structure (total buried surface area of 2050 Å2 (calcu-
lated iG 16.6 kcalmol1)) (23). However, the structure dif-
4 Md. Saiful Islam, unpublished data.
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Figure 3. Evidence that JMJD6 catalyzes hydroxylation of lysine residues from RS-rich regions of SR proteins. MALDI-TOF MS spectra reveal modifica-
tions on JMJD6363– 403-untreated (black lines) and JMJD6363– 403-treated (red lines) peptides from (RS-rich) regions of SR proteins LUC7L2 (A), CROP/LUC7L3
(B), U2AF65 (C), RBM39 (D), Acinus S (E), SRSF11 (F), and LUC7L1 (G). Experiments were carried out following standard hydroxylation assay procedures (see
under “Experimental procedures” for details).
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fers from the structure reported by Hong et al. (43), where
JMJD6 in complex with Fab fragments was observed to crystal-
lize as a monomer (Table S1 and Fig. 5). The combined solution
studies on full-length JMJD6 and variants, including
JMJD6344 – 403, imply the presence of oligomeric states in solu-
tion, including in the dimeric form (21) as observed in our
structure, which of the reported structures may be considered
most likely to represent a catalytically active form of JMJD6.
However, it is also important to note that, as revealed by EM,
electrophoresis, and other methods, JMJD6 can also form
higher oligomerization states for which there is cellular evi-
dence (21). Indeed, nondenaturing MS analysis with full-length
JMJD6 showed masses corresponding to monomeric (48,778 
35 Da), dimeric (97,664  36 Da), trimeric (146,795  15 Da),
tetrameric (209,745  43 Da), and higher oligomerization
states of JMJD6, as observed by EM (21), with the dimer being
the major observed species (Fig. S27).
In agreement with previous JMJD6 structures (23, 43), the
JMJD6344 – 403Fe2OG structure has a distorted DSBH (I–
VIII) core fold (Fig. 4B) characteristic of the 2OG oxygenases,
which is located within the JmjC domain and harbours the Fe-
and 2OG-binding residues. Importantly, the JMJD6344 – 403
Fe2OG structure reveals the geometry of the JMJD6 active-site
coordination chemistry in the presence of its Fe cofactor and
2OG cosubstrate (Fig. 4). The JMJD6 active site and, in partic-
ular, the Fe- and 2OG-binding modes appear to be typical for
the JmjC family of 2OG-dependent hydroxylases. A triad of
residues, His187, Asp189, and His273, forms the metal-binding
motif (Fig. 4C), a feature characteristic of most 2OG oxyge-
nases (Asp is sometimes substituted with Glu or Gly) (1). The
octahedral coordination of the metal is completed by the
oxalyl group of 2OG and a well-defined water molecule (Fig.
4C). JMJD6 His187 and Asp189 are located on the loop linking
II and III, whereas His273 is located on DSBH VII (Fig.
4B). Mutagenesis studies reveal the importance of the Fe-
binding residues in JMJD6 catalysis (Fig. S28B). Although
the JMJD6363– 404D189A variant manifests apparent low-
level formation of succinate in the absence of substrate (Fig.
S28C), succinate formation was not observed in the presence
of LUC7L2267–278 within the limits of detection (Fig. S28C),
implying the D189A variant does not support productive
hydroxylation catalysis. This provides further evidence that
substitution of the metal-binding residues of 2OG oxyge-
nases does not always completely block catalysis; for exam-
ple, in the case of FIH, it has been reported that substitution
of the Fe binding aspartate to a glycine is insufficient to
completely ablate hydroxylation activity (25).
As predicted, but not observed, by Mantri et al. (23), the C-5
carboxylate of 2OG is positioned to form a salt bridge with the
side chain of Lys204 (IV) and to make hydrogen-bonding inter-
actions with residues Tyr131 (located immediately to the N ter-
minus of I), Thr184 (II), and Asn197 (III) (Fig. 4). Similar
Table 2
Kinetic parameters of the JMJD6-catalyzed hydroxylation reactions of SR protein fragments
Experiments were carried out under standard hydroxylation assay conditions with varied concentrations of the substrate (0 – 400 M) (see “Experimental procedures” for
details). Values represent mean  S.D. (n  3).




LUC7L2267–278 NPKRSRSREHRR 12.18 98.5  4.8 51.0  4.6 106  4.0 208
U2AF6521–35 ENRHRKRSHSRSRSR 12.30 74.7  4.1 59.0  8.6 40.0  2.2 68.0
U2AF6530–46 SRSRSRDRKRRSRSRDR 12.48 72.4  6.5 78.0  15 92.0  7.0 118
U2AF6555–70 RDRRRRSKPLTRGAK 12.30 61.0  6.4 124  34 43.0  5.2 34.0
CROP311–325 SRDHKRSRSRERRRS 12.13 89.3  1.9 71.0  7.2 191  6.6 269
CROP341–355 RKHRSRSRDRRRSKS 12.40 92.7  6.9 76.0  13 165  12 217
CROP357–370 DRKSYKHRSKSRDR 11.00 88.7  4.9 93.0  20 39.0  3.6 42.0
SRSF11271–282 SRSRRRSHSKSR 12.60 33.6  1.8 Not determined
SRSF11286–298 RSKSPRRRRSHSR 12.70 90.5  5.0 41.0  6.6 80.0  3.9 195
SRSF11299–310 ERGRRSRSTSKT 12.00 6.40  0.90 Not determined
SRSF11347–360 RSRSGTRSPKKPSR 12.48 97.0  2.2 92.0  14 146  9.6 159
SRSF11358–372 RSPKRKLSRSPSPR 12.48 44.1  3.9 76.0  21 174  19 229
RBM3931–42 RSKKRKKSKSRS 12.32 99.0  0.70 56.0  9.6 255  15 455
RBM3938–50 SKSRSRSHERKRS 12.01 79.0  8.9 71.0  9.9 281  15 395
RBM3951–62 KSKERKRSRDRE 10.93 37.0  7.6 Not determined
RBM3971–82 RKRSRSKERRRS 12.30 87.6  7.0 88.0  8.7 284  11 322
RBM39121–132 SRRRSRSKSPFR 12.60 82.5  5.6 99.0  19 300  23 303
LUC7L1287–298 SRERRKLSRSRSR 12.30 18.3  3.1 Not determined
Acinus S447–460 PRSRSRSRDRRRKE 12.13 25.6  2.8 Not determined
Acinus S95–604 KRHSRSRSRS 12.48 12.5  3.0 Not determined
Table 3




X-Ray source DLS I02
Wavelength (Å) 1.07206
Resolution (Å) 42.22–2.04 (2.11–2.04)
Space group P1211
Unit cell dimensions
a, b, c 47.15, 96.99, 93.76
, ,  90.00, 95.84, 90.00
Molecules/asymmetric unit 2










Deviation from idealized geometry
Bond length (Å) 0.003




a High resolution bin was used.
b 4.9% of the total reflections used for Rfree calculations is shown.
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conformations for Tyr131 and Thr184 were observed in 3K2O
(23), wherein 2OG was absent and where an acetate ion modeled
at the active site is positioned to interact with the side chain of
Lys204 (Fig. 5). Thus, our combined results imply an apparently
typical JmjC 2OG-binding mode for JMJD6. By contrast, in the
JMJD6Fab fragment complex structure (PDB code 3LDB), as
reported by Hong et al. (43), the position of 2OG is different from
that observed in other 2OG oxygenase crystal structures, i.e. it is
relatively distant from the metal and appears to have a poor geom-
etry to form the typical octahedral coordination observed in
Figure 4. Crystallographic studies of the JMJD6344 – 403Fe2OG complex. A, surface and cartoon representations of a crystal structure of the JMJD6344 – 403
homodimer (PDB code 6GDY). B, JMJD6 core 8 -strands of the DSBH fold are highlighted red and labeled as standard roman numerals I–VIII (yellow circles);
with its cofactor iron shown as an orange sphere, and cosubstrate 2OG and active-site residues shown as sticks. C, views of the JMJD6 iron- and 2OG-binding
residues. The left panel shows difference electron density mFo  DFc OMIT map (green mesh) contoured to 3	. Right panel shows ligand interaction (black
dashes) distances in angstroms (blue).
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2OG oxygenaseFe2OG complexes (Fig. 5D). Note in the
JMJD6344 – 403Fe2OG structure, the 2OG C-1 carboxylate is
trans to the distal His273 of the binding triad (His273JMJD6) rather
than being trans to the proximal His187 (His187JMJD6), as is also
observed in FIH, JMJD5, JMJD2A, and PHF8 (e.g. His199FIH,
His321JMJD5, His188JMJD2A, and His247PHF8) structures (Fig. 6).
Figure 5. Comparison of reported crystal structures for JMJD6. Cartoon representations of high resolution crystal structures of anaerobic JMJD6 in complex with
iron and 2OG, JMJD6344–403Fe2OG (PDB code 6GDY) (A), compared with aerobic JMJD6 in complex with nickel and acetate, JMJD6344–403Niacetate (PDB code
3K2O) (23) (B), an aerobic FAB fragment, JMJD6, and Fe complex, JMJD6FLFe (PDB code 3LD8) (43) (C), and low-resolution aerobic FAB fragment, JMJD6, 2OG, and Fe
complex, JMJD6FLFe2OG (PDB code 3LDB) (43) (D) are shown. The insets show differences observed in the 2OG/ligand-binding residues in the different crystal
structures. D, left panel shows a comparison of the active sites from PDB structures 3LDB (orange) and 6GDY (green). Middle panel, note the absence of electron density
for 2OG in 3LDB compared with Fig. 4C, left panel, showing high resolution structure 6GDY. Act  acetate.
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This variation likely does not impact the general mode of iron
binding, but it has the potential to direct the binding of the
incoming O2 trans to either the proximal or distal metal-bind-
ing histidine depending on the coordination site vacancy. The
position of O2 binding might play roles in substrate recognition
and in regulating the types of reactions that 2OG oxygenases
are able to catalyze (2, 13, 44, 45).
Analysis of the electrostatic surface potential (46) of the
JMJD6344 – 403 structure reveals that its active site has an overall
negative charge (Fig. 7A). This is similar to other structurally char-
acterized JmjC domain-containing proteins (Fig. 7, B–E) and likely
contributes to the ability of JMJD6 to bind the positively charged
basic groups of its substrate lysyl side chain as well as other lysyl-/
arginyl-residues in the (typically) basic JMJD6 substrates, e.g. his-
tones and RS domains of SR proteins.
Following the observation of ordered sulfate molecules at
conserved positions across positively-charged sites on the sur-
face of JMJD6 (Fig. S29), Hong et al. (43) proposed JMJD6
directly binds oligonucleotides, specifically single-stranded
RNA. Consistent with this observation in the JMJD6344–403
Fe2OG structure, we observed binding of phosphate ions in
similar locations on the protein surface (Fig. S29), with basic
residues involved in these interactions, including Lys4, Lys7,
Arg8, Arg48, Lys91, Arg92, Arg95, Lys111, Lys115, Lys144, Lys151,
Lys154, Arg305, Lys307, and Arg310 (Fig. S29).
Discussion
The combined biochemical and structural studies, includ-
ing those reported here, are fully supportive of the assign-
ment of JMJD6 as a 2OG oxygenase (14). The structure of a
JMJD6344 – 403Fe2OG complex obtained under anaerobic
conditions presented here contrasts with a previously reported
structure (43) in that it reveals that the active-site region of JMJD6
is most similar to known hydroxylases and, more specifically the
JmjC subfamily, with respect to the observed Fe- and 2OG-bind-
ing modes (Fig. 4). The overall negative charge in the active-site
substrate-binding region (Fig. 7) is complementary to the primar-
ily basic nature of JMJD6 substrates that have been reported,
including histones (15, 32) and RS-rich regions of SR proteins
(17). Further analysis shows that the overall architecture of the
JMJD6 active site shows greater resemblance to reported JmjC
hydroxylases, i.e. those giving indefinitely stable alcohol products,
than to the JmjC KDMs. JmjC hydroxylases include FIH (24),
JMJD5 (12), and JMJD7 (11), all of which form oligomers and man-
ifest a lack of additional substantial discrete domains (Fig. 6). The
JMJD6 structural features are more like the JmjC hydroxylases
than the KDMs.
Our structural work supports the oligomeric state of JMJD6
as a dimer, in contrast to a monomeric JMJD6 structure
reported by Hong et al. (43), although a caveat of the latter
structure is that it is in complex with a Fab fragment, the bind-
ing of which interferes with the dimerization interface. Wolf
et al. (21) reported the presence of dimeric and higher oligo-
meric forms of JMJD6 in a cellular context. Most, if not all, JmjC
KDMs (and potential RDMs) contain additional domains to the
JmjC/DSBH core fold, e.g. PHF8 (KDM7B), which has an addi-
tional PHD, and the JMJD2 (KDM4) JmjC KDMs (47, 48),
which contain JmjN and tudor domains (Fig. 6) (48). However,
aspects of the JMJD6 structure, including the role of its charac-
teristic poly-Ser domain in oligomerization (21), appear to be
unique among characterized 2OG oxygenases.
As experience shows with 2OG oxygenases, it is imprudent to
predict catalytic function based on sequence/structure; even when
there is exceptionally high identity, different reactions with closely
related enzymes are possible (2, 49); by way of example, one mem-
ber (TYW5, the transfer ribonucleic acid wybutosine-synthesizing
protein 5) of the JmjC subfamily of 2OG oxygenases, which typi-
cally acts as protein hydroxylase, has been shown to act on a
nucleic acid (50). Thus, our view is that it is important that bio-
chemical studies with isolated enzymes are carried out to define
the reactions catalyzed by purified 2OG oxygenases. Although
substrate identity/selectivity may well differ in a cellular context
compared with that observed for an isolated enzyme, e.g. due to the
presence of targeting domains/proteins, knowledge of the types of
reaction directly catalyzed by the 2OG oxygenase domain in vitro
can assist in subsequent functional assignment work in vivo. Given
its checkered history (14), this is arguably particularly important
for JMJD6.
Following the identification of an appropriate JMJD6 con-
struct (JMJD6363– 403), we carried out studies on reported
JMJD6 N-methyl arginyl “demethylation” and lysyl “hydroxyl-
ation” substrates (Figs. 2 and 3, Figs. S14, S22–S26, and Table
S2). In our studies, we found no evidence that purified JMJD6
has N-methyl arginyl demethylase (RDM) activity (Table S2).
Positive controls for RDM activity employing KDM4E (4) were,
however, successful (Fig. 2). Unlike the proposed RDM func-
tion of JMJD6, the lysyl hydroxylase function of purified JMJD6
was clearly reproducible with a range of substrates, including
SR protein fragments (17), histone fragments (15, 17, 32), and
the von Hippel-Lindau protein (pVHL) (Table S2) (37). In addi-
tion to JMJD6 lysyl hydroxylase activity on peptides, activity
was also observed on full-length recombinant and endogenous
U2AF65 (17) as well as on endogenous histones (32). Thus,
we conclude that, at least under our assay conditions, iso-
lated JMJD6 is a lysyl hydroxylase, with no evidence for
RDM, nor indeed KDM, activity. Chang et al. (15) have
reported JMJD6 RDM activity on histones, which they
observed using an assay involving the use of antibodies and
MS. However, cross-reactivity data for the antibodies used in
Figure 6. Comparison of the JMJD6 crystal structure with those of related 2OG oxygenases. Cartoon representations and domain architectures are shown
for JMJD6344 – 403Fe2OG (PDB code 6GDY) (A), compared with JmjC hydroxylases, FIHFe2OGHIF-1CAD795– 822 (PDB code 1H2L) (B) (24),
JMJD5CoNOGRpS6129 –144 (PDB code 6F4P) (C) (12) and JmjC demethylases, JMJD2A (KDM4A).Ni2HGH3K36(me3)30 – 41 (PDB code 2YBP) (D) (64), and
PHF8(KDM7B)FeNOGH3K4(me3)1–24 (PDB code 3KV4) (E) (47). In each enzyme, the core 8 -strands of the DSBH are in gray and labeled (white circles), and
other -strands are in red unless part of a different domain (i.e. PHF8 PHD domain in orange). IV–V insert regions are highlighted with blue helices. The insets
show an expanded view of the active sites of related enzymes comparing the orientation of substrates (yellow sticks and surfaces), metal (spheres) and
interacting residues (sticks colored by region as in cartoon and topology). The locations of metal-binding residues highlighted in topology diagrams (right
panels) are shown with yellow stars.
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this study have not been reported. Importantly, the Chang et
al. (15) MS data also show evidence for JMJD6-catalyzed
hydroxylation of histone peptides. It shall also be noted that
JMJD6 can also undergo self-oxidation, involving lysyl hy-
droxylation (34), and that its biological roles may involve
stoichiometric as well as catalytic processes (21).
In addition to multiple SR domain substrates (Fig. 3), we found
other reports of JMJD6 lysyl hydroxylase activity to be reproduci-
Figure 7. Comparison of electrostatic surface potential of JMJD6 with those of other 2OG oxygenases. Electrostatic surface potentials for the crystal
structures of JmjC hydroxylases are as follows: A, JMJD6344 – 403Fe2OG (PDB code 6GDY); B, JMJD5CoNOG (PDB code 4GJZ) (65); C, FIHFe2OG (PDB code
1H2N) (24) and JmjC demethylases; D, PHF8(KDM7B)Fe2OG (PDB code 3K3O) (66); E, JMJD2A(KDM4A)Fe2OG (PDB code 2GP5) (67). Note the phosphates
(from the crystallization buffer) bound at complementary basic regions may indicate locations of nucleic acid phosphate backbone-binding sites.
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ble (Table S2). Lys382 of the tumor-suppressor protein p53 is
reported to be hydroxylated by JMJD6 (35), and we reproduced
this using JMJD6363–404 incubated with p53 peptide fragments
(Fig. S26). Peptide fragments of two other biochemically impor-
tant reported targets, i.e. pVHL and ER (28, 37), were also vali-
dated as JMJD6 lysyl hydroxylation substrates (Figs. S24 and S25).
Although we did not observe JMJD6-catalyzed RDM activity on
ER as was reported (28), hydroxylation of Lys252 and Lys257 in
ER peptide fragments did occur (Fig. S25).
pVHL is a tumor-suppressor protein in kidneys, which has a
crucial role in dioxygen dependent proteasome-mediated deg-
radation of prolyl-hydroxylated forms of -subunits of the
transcription factor HIF in many animal cells (24, 51, 52). In
normoxia, HIF is efficiently degraded, whereas proteasomal
degradation of HIF- subunits is slowed because the associa-
tion between pVHL and HIF1 is diminished due to reduced
PHD prolyl hydroxylation activity (24, 51, 52). The results pre-
sented here suggest further cell-based studies investigating the
potentially pleiotropic roles of JMJD6 lysyl hydroxylation (and
potentially other activities) beyond histones and splicing regu-
latory proteins are merited. Given the established role of pVHL
in 2OG oxygenase–mediated hypoxia sensing, its interactions
with JMJD6 may be of particular interest.
Experimental procedures
Purification of JMJD6
DNA encoding for the N-terminal His6-tagged human full-
length JMJD6 (aa 1– 403, JMJD6FL) was inserted into the
pET28a() expression vector. Expression plasmids for two
more variants (aa 1–362, JMJD6363– 403, and aa 1–343,
JMJD6344 – 403) were prepared by inserting a stop codon after
the desired site using site-directed mutagenesis (see Table S3
for primer sequences). JMJD6 variants were expressed in Esch-
erichia coli Rosetta2(DE3) cells (17, 23). Cells were grown in 2	
tryptone/yeast extract (2TY) media supplemented with 30
g/ml kanamycin and 34 g/ml chloramphenicol at 37 °C to an
A600  1.0; expression was initiated by adding 0.5 mM isopropyl
-D-thiogalactopyranoside. Growth was continued at 16 °C for
another 16 –18 h; cells were harvested by centrifugation
(10,000 	 g, 8 min) and stored at 80 °C. Cell pellets were
resuspended in lysis buffer (50 mM Tris, pH 7.5, 200 mM NaCl,
10 mM imidazole, 10% glycerol, 4 mM MgCl2, EDTA-free pro-
tease inhibitor mixture tablet (Roche Applied Science), DNase I
(bovine pancreas, grade II, Roche Applied Science), and 0.5% Non-
idet P-40). The lysates were loaded onto a 5-ml HisTrap column
(GE Healthcare), equilibrated with binding buffer (50 mM Tris, pH
7.5, 200 mM NaCl, 10 mM imidazole, 10% glycerol, and 0.5% Non-
idet P-40) using an AKTA purifier (GE Healthcare). The column
was washed with wash buffer (50 mM Tris, pH 7.5, 200 mM NaCl,
100 mM imidazole, 10% glycerol, and 0.5% Nonidet P-40). JMJD6
was eluted with elution buffer (50 mM Tris, pH 7.5, 200 mM NaCl,
500 mM imidazole, 10% glycerol, and 0.5% Nonidet P-40) using a
linear gradient (0–100%). Based on UV-trace (280 nm) and SDS-
PAGE analyses, fractions with purified JMJD6 were pooled and
concentrated to 2 ml using a membrane filter (30-kDa molecular
mass cutoff membrane). Concentrated protein was loaded onto a
Superdex 200 size-exclusion column (GE Healthcare), pre-equili-
brated with size-exclusion buffer (50 mM Tris, pH 7.5, 200 mM
NaCl, and 5% glycerol), for further purification. The desired frac-
tions (based on UV-trace and SDS-PAGE analyses) were concen-
trated to 25–30 mg/ml, then flash-frozen in liquid nitrogen, and
stored at 80 °C. Catalytic mutants of the variant JMJD6363–403
were prepared by site-directed mutagenesis (see Table S3 for
primer sequences) and were purified by following the same puri-
fication procedure as for WT.
CD spectroscopy
CD spectra were acquired using a Jasco J-815 spectrometer
(Jasco). Protein solutions were buffered with 10 mM phosphate
buffer, pH 8.0. Spectra were acquired using a quartz cuvette
with a 0.1-cm path length, between 260 and 185 nm at 0.2
nmmin1 increments, a response time of 1 s, and a data pitch
of 0.5 nm. Spectra were averaged over four scans and cor-
rected for solvent background. To investigate secondary
structure content, the CD secondary structure deconvolu-
tion method was applied to the data, which were accessed
using the DICHROWEB server (53, 54).
NMR-based 2OG turnover assays
2OG turnover assays employed a reported procedure (4). 10
M JMJD6, 100 M (NH4)2Fe(SO4)26H2O (Sigma), and 400 M
L-sodium ascorbate (Sigma) were mixed in deuterated Tris-d11
(Sigma), pH 7.5, in a 1.5-ml Eppendorf tube. Substrate (either
only 500 M 2OG or a mixture of 500 M 2OG and 100 M
LUC7L2267–278) was added to initiate the reaction. The mixture
was immediately transferred into a 2-mm NMR tube, and the
acquisition of 1H spectra was started after 3.5–5 min.
NMR-based binding constant (KD
app) determination for 2OG
20 M 2OG and 200 M Zn(II) were mixed in deuterated
Tris-d11, pH 7.5, and the 1H NMR signals for 2OG were
recorded at 700 MHz (39). Titration using EDTA-treated
JMJD6 (with added Zn(II)) was performed until the signals for
2OG disappeared, suggesting JMJD6Zn(II)2OG complex for-
mation. The percentage of this complex was then plotted as a
function of enzyme concentration using Origin (OriginLab
Corp.), and the apparent binding constants (KDapp) were mea-











where obs represents change in an observable NMR parameter
from the titration; total represents the total change of the mon-
itored NMR parameter; [L]0 represents the titrated ligand con-
centration; and [P]0 represents the protein concentration. Typ-
ically, a 5–10% error was allowed in the curve-fitting process.
NMR-based CPMG displacement experiments
CPMG displacement experiments used a Bruker AV700 NMR
machine, as reported previously (39). The PROJECT (Periodic
Refocusing of J Evolution by Coherence Transfer)-CPMG
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sequence (90°x  (  180°y    90°y    180°y  )n 
acquisition) was applied (56). Typical parameters were as follows:
total echo time 48 ms (  2 ms, n  6); acquisition time 2.94 s;
relaxation delay 2 s; number of transients 128. Water suppression
was achieved by presaturation (57, 58).
Standard MS-based hydroxylation assays
JMJD6 activity was assayed using a reaction mixture of 10 M
purified JMJD6 and 100 M substrate peptide, at 37 °C in 50
mM HEPES-KOH, pH 8.0, buffer supplemented with 100 M
(NH4)2Fe(SO4)26H2O (Sigma), 400 M L-sodium ascorbate
(Sigma), and 500 M disodium 2OG (Fluka). After 30 min,
the reaction was quenched by an equal volume of 1% (v/v)
aqueous formic acid (Sigma). In a 96-well MALDI plate
(Waters), 0.8 l of CHCA (-cyano-4-hydroxycinnamic
acid, Aldrich) (1 g in 0.1 ml of CHCA solvent) and 0.6 l of
the quenched mixture were placed in a well. After drying, the
samples were analyzed by MALDI-TOF MS using a reported
procedure (59, 60). The kinetic data obtained thereafter were
fitted using GraphPad Prism (GraphPad Software) (59, 60).
Standard MS-based demethylation assays
Demethylation assays were carried out using JMJD6 and
potential substrate peptides at 37 °C in 50 mM HEPES-KOH,
pH 8.0 buffer, supplemented with 20 M (NH4)2Fe(SO4)26H2O
(Sigma), 500 M L-sodium ascorbate (Sigma), and 1 mM di-
sodium salt of 2OG (Fluka) for 1 h or more (15, 27, 40).
Reaction samples were thereafter analyzed by MALDI-TOF
or LC-MS/MS.
LC-MS/MS analyses
Samples were desalted using a ZipTip (Millipore) and then
analyzed using a NanoAcquity-ultraperformance liquid chro-
matography system (Waters) connected to an Orbitrap Elite
mass spectrometer (Thermo Fisher Scientific), possessing an
EASY-Spray nano-electrospray ion source (Thermo Fisher Sci-
entific). Peptides were “trapped” on an in-house packed guard
column (75-m inner diameter 	 20 mm, Acclaim PepMap
C18, 3 m, 100 Å) using solvent A (0.1% (v/v) aqueous formic
acid) at a pressure of 140 bar. Peptides were separated on an
EASY-Spray Acclaim PepMap analytical column (75 m
inner diameter 	 15 mm, rapid separation liquid chromatog-
raphy C18, 3 m, 100 Å) using a linear gradient (length, 100
min; 3– 60% solvent B (0.1% formic acid in acetonitrile), flow
rate, 300 nl/min). The separated peptides were electro-sprayed
directly into the spectrometer operating in a data-dependent
mode using a collision-induced dissociation/electron transfer
dissociation (CID/ETD)-based method. Full scan MS spectra
(scan range 150 –2000 m/z, resolution 30,000, AGC target 1 	
106, maximum injection time 250 ms) and subsequent CID
MS/MS spectra (AGC target 3 	 104, maximum injection time
500 ms) of the 10 most intense peaks were acquired in the
Orbitrap. CID fragmentation was performed at 35% of the nor-
malized collision energy, and the signal intensity threshold was
kept at 500 counts. ETD spectra (AGC cation target 5 	 104,
AGC anion target 2 	 105, and cation maximum injection time
100 ms) were acquired in the ion trap. PEAKS 8.0 (Bioinfor-
matics Solutions, Inc., Waterloo, Canada) was used to analyze
raw data. The raw MS files were searched against the respective
proteinsequences.NONEwasselectedastheprotease.Demeth-
ylation (14 and 28 Da) and hydroxylation (16, 32, and
48 Da) were set as variable modifications. The precursor mass
tolerance was 15 ppm. The fragment mass tolerances for CID
and ETD were set to 0.8 Da. All spectral assignments were man-
ually validated.
Crystallization and structure determination of JMJD6344 – 403
Crystallization trials were performed using commercially avail-
able broad screens followed by optimization. JMJD6344–403
of high purity (95%, based on SDS-PAGE analysis) at a con-
centration of 25 mg/ml (500 – 600 M) was used.
JMJD6344 – 403metalligand complexes were formed by incu-
bating enzyme with the other components (typically in 5-fold
excess) on ice for 1 h. A PhoenixTM RE crystallization robot
(Art Robbins Instruments) and a Minstrel-HTTM platform with
CrystalTrekTM (Rigaku Inc., Japan) were used to prepare and
monitor crystallization trials. Crystals were grown using the
sitting-drop vapor-diffusion method (61) either in 96-well low-
profile intelliplates (Art Robbins Instruments) (drop size, 200 –
300 nl) at room temperature or in 24-well Linbro sitting-drop
plates (drop size 1000 nl) in an anaerobic glovebox (Belle Tech-
nologies, Dorset, UK) to avoid turnover during crystallization
as reported previously (24). The optimized crystallization con-
dition contained 0.1 M HEPES buffer, pH 7.8, 0.7 M sodium
phosphate monobasic, 0.9 M potassium phosphate monobasic,
and 3% glycerol. This crystallization condition was obtained
from optimization of an initial hit from a broad screen (Hamp-
ton Research Crystal Screen HT, no. 35). Crystals were cryo-
protected using a mixture of reservoir solution diluted to 25%
(v/v) glycerol and cryo-cooled by plunging into liquid nitrogen.
Diffraction data were collected at 100 K at the Diamond Light
Source synchrotron. PHASER was used for molecular replace-
ment using PDB code 3K2O (23) as the search model; the struc-
tural model was improved by iterative cycles of manual
re-building in COOT and crystallographic refinement in
PHENIX (Python-based Hierarchical Environment for Inte-
grated Xtallography) (62, 63).
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